Literature DB >> 6244073

The role of curative radiotherapy in the treatment of lung cancer.

P Coy, G M Kennelly.   

Abstract

From 1963-1974, 141 patients with lung cancer were treated with curative intent in the A. Maxwell Evans Clinic in Vancouver. The clinical presentation, age and sex distribution, histology, and reasons for surgery not being carried out are examined. The results of this treatment are presented. An attempt has been made to isolate a group of patients who have a better prognosis so that treatment selection can be improved. Hemoptysis, cough, dyspnea, and incidental finding on routine chest x-ray were the most common manner of presentation. Thirty-four percent of the patients were over 70 years of age and 13% were women. The crude overall three- and five-year survival rates were 18 and 10% (19 and 9% in the men, 17 and 14% in the women). Patients presenting with dyspnea had a better survival than those presenting with cough and hemoptysis. Patients with lesions less than 3 cm in diameter had a 28% three-year survival, compared with 14% for lesions greater than 5 cm in diameter. The three- and five-year survival rates in patients over 70 years of age were 23 and 17% respectively. The response to treatment and the survival was better in the patients with squamous cell carcinoma. Twenty-two percent were alive at three years and 12% at five years as compared with 9 and 5% for other histologies. Fifty-four percent of the 35 patients with a complete response and with squamous cell carcinoma were alive at three years, compared with only 8% of the 12 patients with other histologies who showed a complete response.

Entities:  

Mesh:

Year:  1980        PMID: 6244073     DOI: 10.1002/1097-0142(19800215)45:4<698::aid-cncr2820450414>3.0.co;2-8

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Management of lung cancer.

Authors:  S G Spiro
Journal:  BMJ       Date:  1990-12-08

2.  Dosimetric verification using monte carlo calculations for tissue heterogeneity-corrected conformal treatment plans following RTOG 0813 dosimetric criteria for lung cancer stereotactic body radiotherapy.

Authors:  Jun Li; James Galvin; Amy Harrison; Robert Timmerman; Yan Yu; Ying Xiao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-24       Impact factor: 7.038

3.  An orthotopic lung tumor model for image-guided microirradiation in rats.

Authors:  Debabrata Saha; Linda Watkins; Yi Yin; Philip Thorpe; Michael D Story; Kwang Song; Pavithra Raghavan; Robert Timmerman; Benjamin Chen; John D Minna; Timothy D Solberg
Journal:  Radiat Res       Date:  2010-07       Impact factor: 2.841

4.  [Lung cancer--hopelessness in inoperability? A 10-year follow-up].

Authors:  N Schwegler
Journal:  Strahlenther Onkol       Date:  1997-07       Impact factor: 3.621

Review 5.  New era of radiotherapy: an update in radiation-induced lung disease.

Authors:  M F K Benveniste; J Welsh; M C B Godoy; S L Betancourt; O R Mawlawi; R F Munden
Journal:  Clin Radiol       Date:  2013-03-06       Impact factor: 2.350

6.  Effectiveness of radiation therapy for elderly patients with unresected stage I and II non-small cell lung cancer.

Authors:  Juan P Wisnivesky; Ethan Halm; Marcelo Bonomi; Charles Powell; Emilia Bagiella
Journal:  Am J Respir Crit Care Med       Date:  2009-11-05       Impact factor: 21.405

7.  A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.

Authors:  Mark A Henderson; David J Hoopes; James W Fletcher; Pei-Fen Lin; Mark Tann; Constantin T Yiannoutsos; Mark D Williams; Achilles J Fakiris; Ronald C McGarry; Robert D Timmerman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-25       Impact factor: 7.038

8.  Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer.

Authors:  Ying Xiao; Lech Papiez; Rebecca Paulus; Robert Timmerman; William L Straube; Walter R Bosch; Jeff Michalski; James M Galvin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-15       Impact factor: 7.038

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.